RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
  Anorexia Nervosa
  Anxiety
  Bulimia
  CFS
  Child Psychiatry
  Depression
  Forensic Psychiatry
  Learning-Disabilities
  Mood Disorders
  Neuropsychiatry
  Peri-Natal Psychiatry
  Personality Disorders
  Psychology
  Psychoses
  Psychotherapy
  Sleep Disorders
  Substance Abuse
   Alcohol
   Amphetamine
   Cannabis
   Cocaine
   Opiates
   Smoking
  Suicide
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Alcohol Channel

subscribe to Alcohol newsletter
Latest Research : Psychiatry : Substance Abuse : Alcohol

   EMAIL   |   PRINT
Once-a-month naltrexone successfully used to treat alcohol dependence

Apr 8, 2005 - 1:43:00 AM
"The decision to take medication can wane over time. This provides coverage for an entire month."

 
[RxPG] Long-acting injections of the drug naltrexone, combined with psychotherapy, significantly reduced heavy drinking in patients being treated for alcohol dependence, according to a study in the Journal of the American Medical Association by a Yale School of Medicine researcher.

"The decision to take medication can wane over time," said Stephanie O'Malley, professor of psychiatry and director of the Division of Substance Abuse Research at the Connecticut Mental Health Center at Yale. "This provides coverage for an entire month."

Acohol dependence ranks as the fourth leading cause of disability worldwide, as reported by the World Health Organization's Global Burden of Disease project. Nationwide, it is believed to contribute to more than 100,000 preventable deaths a year.

Naltrexone belongs to a class of drugs called opioid antagonists. Although many clinical trials have shown that oral naltrexone can be effective in treating alcohol dependence, its use in clinical practice has been limited, in part patients have to take the pill daily.

In this trial conducted at 24 sites, 627 alcohol dependent patients were randomly assigned to receive either an injection of long-acting naltrexone or a placebo injection; 624 ultimately received at least one injection. All participants received 12 counseling sessions during the six-month study in addition to the medication. Long-acting naltrexone was associated with a reduction in heavy drinking within the first month of treatment, and this response was maintained over the six month treatment period.



Publication: Journal of the American Medical Association (April 6, 2005)
On the web: www.yale.edu 

Advertise in this space for $10 per month. Contact us today.


Related Alcohol News
Genetics may increase propensity for alcoholism
Gene mutation in worms key to alcohol tolerance
Researchers identify alcoholism subtypes
Women drinkers could face more depression
Orexin reinforces the euphoria felt when drinking alcohol
DNA highly-promising predictor for successful treatment of alcoholics
Nicotine may actually reduce blood alcohol concentrations
Alcoholics' deficits in smell are linked to frontal lobe dysfunction
Asp carriers of the OPRM1 gene taking naltrexone have increased urge to drink
Early Drinking Linked to Risk of Alcohol Dependence

Subscribe to Alcohol Newsletter

Enter your email address:


 Additional information about the news article
The lead author was James Garbult, M.D., of the University of North Carolina School of Medicine.

The study was funded by Alkermes Inc., a biotechnology company based in Cambridge, Mass., that manufactures the long acting naltrexone formulation.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)